Investing for Launch Success: What Matters Most (and When)

Fewer than 40% of new product launches meet their target forecasts—a success rate that puts significant stress of every decision about where to spend money and when. Syneos Health has explored this topic through six years on launch spend data analyses and research with biopharmaceutical and financial executives to understand optimal levels of launch investment.

This white paper reports results from a recent analysis to understand current trends in launch spending. For example, companies now need to spend at least 125% of their first-year forecast in the year before launch to succeed—up from a <75% spend threshold five years ago. This new analysis also takes a closer look at functions that today’s biopharmaceutical executives say are most frequently underinvested in or invested in too late, and offers actionable recommendations for optimizing launch spend.

Explore the full report to discover the keys to making a “just right” level of spend that will increase your probability of launch success.